Breast cancer is the number one cause of cancer-related deaths among females. Current chemotherapy targets both tumor and normal cells, leading to pronounced side effects. Therefore, therapeutic vaccines acting against specific cancer cells would be the choice of treatment. We prepared microparticles entrapping the antigens obtained from a murine metastatic breast cancer cell line, 4 T1 using the spray drying technology. These microparticles were incorporated into microneedle patches to deliver to the animals for the efficacy study. An antineoplastic drug, cyclophosphamide, in a very low dose has been found to inhibit the immunosuppressive regulatory T cells (Treg) (Le and Jaffee, 2012). In-vivo efficacy of the microparticulate vaccine given along with a low dose of cyclophosphamide was evaluated in a murine breast cancer model. Animals immunized with vaccine microparticles showed considerably slower tumor growth than animals that did not receive the vaccine. The results of the study showed that the Tumor-Associated Antigens (TAAs) within the microparticles were responsible for the delayed tumor growth in vaccinated animals. Vaccinated animals also showed an increase in the population of CD4 and CD8 T cells. Overall, our results demonstrated that immunotherapy with vaccine microparticles encapsulating TAA's could potentially be an effective treatment for metastatic breast cancer.
Keywords: Immunotherapy; Metastatic breast cancer; Microparticle; Spray Drying; Therapeutic Vaccine.
Copyright © 2022 Elsevier B.V. All rights reserved.